Litcius/Paper detail

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2

Weijuan Shang, Wenhao Dai, Cheng Yao, Ling Xu, Xiangming Tao, Haixia Su, Jian Li, Xiong Xie, Yechun Xu, Min Hu, Dong Xie, Hualiang Jiang, Leike Zhang, Hong Liu

2022Antiviral Research39 citationsDOIOpen Access PDF

Topics & Concepts

In vivoVero cellIn vitroEC50Ex vivoPharmacologyChemistryIC50Protease inhibitor (pharmacology)TiterMolecular biologyVirologyBiologyVirusViral loadBiochemistryAntiretroviral therapyBiotechnologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesComputational Drug Discovery Methods
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2 | Litcius